BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
VANCOUVER, BC, May 16, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) announces that the Ontario Securities Commission (the “OSC“) has issued a failure to file cease trade order (“FFCTO“) under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions (“NP 11-207“), prohibiting the trading by any person of any securities of the Company in Canada, including trades in the Company’s common shares made through the Canadian Securities Exchange.
Related news for (BVAXF)
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Granted Management Cease Trade Order
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
- BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT